IRD — Opus Genetics Share News
0.000.00%
Last trade - 00:00- $317.81m
- $265.20m
- $14.20m
Ocuphire Pharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Ocuphire Pharma Announces Financial Results For First Quarter 2023 And Provides Corporate Update
Ocuphire Pharma Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Ocuphire Provides Corporate Update And Reiterates Previous Guidance On Clinical Programs
Ocuphire Pharma shares fall on appointment of interim CEO
Brief: Ocuphire Appoints Rick Rodgers As Interim Chief Executive Officer
U.S. RESEARCH ROUNDUP-Heska, Prudential Financial, ServiceNow
Brief: Ocuphire Pharma Believes Cash On Hand Sufficient To Fund Operations In 2025
Ocuphire Pharma Inc expected to post earnings of 97 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Ralph Lauren, Howmet, Insulet
U.S. STOCKS ON THE MOVE-Top Ships, Brightcove, Airbnb
Ocuphire Pharma rises as FDA accepts marketing application for eye drug
Brief: Ocuphire Announces FDA Acceptance Of New Drug Application
U.S. STOCKS ON THE MOVE-Foot Locker, Nemaura, Chipotle
Ocuphire falls as diabetes-related eye disease drug fails main study goal
U.S. STOCKS ON THE MOVE-TD Synnex, Nucor, Pfizer
U.S. STOCKS ON THE MOVE-Xerox, AC Immune, OpGen
Ocuphire Pharma tanks as diabetes-focused eye drug fails to meet main goal
Brief: Ocuphire Says Diabetic Retinopathy Drug Did Not Meet Primary Endpoint